CR11523A - Agentes fijadores y epitopos wise - Google Patents

Agentes fijadores y epitopos wise

Info

Publication number
CR11523A
CR11523A CR11523A CR11523A CR11523A CR 11523 A CR11523 A CR 11523A CR 11523 A CR11523 A CR 11523A CR 11523 A CR11523 A CR 11523A CR 11523 A CR11523 A CR 11523A
Authority
CR
Costa Rica
Prior art keywords
agents
epithope
wise
wise fixing
fixing
Prior art date
Application number
CR11523A
Other languages
English (en)
Inventor
Qian Xueming
Graham Kevin
Shimamoto Grant
S Tipton Barbara
Tsai Mei-Mei
George Winters Aaron
Zhang Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR11523A publication Critical patent/CR11523A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a agentes de fijacion para WISE e incluye su manufactura y uso.
CR11523A 2007-11-21 2010-06-21 Agentes fijadores y epitopos wise CR11523A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US403707P 2007-11-21 2007-11-21

Publications (1)

Publication Number Publication Date
CR11523A true CR11523A (es) 2010-12-16

Family

ID=40524859

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11523A CR11523A (es) 2007-11-21 2010-06-21 Agentes fijadores y epitopos wise

Country Status (17)

Country Link
US (2) US8043620B2 (es)
EP (1) EP2220118A2 (es)
JP (2) JP5583591B2 (es)
KR (1) KR20100099193A (es)
CN (1) CN101925611A (es)
AU (1) AU2008330125B2 (es)
BR (1) BRPI0820387A2 (es)
CA (1) CA2705879A1 (es)
CO (1) CO6311002A2 (es)
CR (1) CR11523A (es)
EA (1) EA201000844A1 (es)
IL (1) IL205569A0 (es)
MA (1) MA31918B1 (es)
MX (1) MX2010005656A (es)
TN (1) TN2010000213A1 (es)
WO (1) WO2009070243A2 (es)
ZA (1) ZA201003578B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3489257A1 (en) 2004-07-23 2019-05-29 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
EP2781222B1 (en) 2005-11-23 2017-08-02 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
CA2677007A1 (en) 2007-02-01 2008-08-07 Acceleron Pharma Inc. Activin-actriia antagonists and uses for treating or preventing breast cancer
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
EP2481415B1 (en) 2007-02-09 2019-09-11 Acceleron Pharma Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists
JP2010539236A (ja) 2007-09-18 2010-12-16 アクセルロン ファーマ， インコーポレイテッド アクチビン−ＡｃｔＲＩＩａ拮抗薬およびＦＳＨ分泌を低減または阻害するための使用
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
WO2011063127A1 (en) 2009-11-18 2011-05-26 University Of Medicine And Dentistry Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
JP5912078B2 (ja) 2009-06-08 2016-04-27 アクセルロン ファーマ， インコーポレイテッド 熱発生性脂肪細胞を増加させるための方法
EP3290439B1 (en) 2009-06-12 2020-09-02 Acceleron Pharma Inc. Truncated actriib-fc fusion proteins
US8623358B2 (en) 2009-08-29 2014-01-07 Abbvie Inc. Therapeutic DLL4 binding proteins
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US9849192B2 (en) 2009-11-18 2017-12-26 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to matriptase antibodies
RU2016105962A (ru) * 2009-12-04 2018-11-23 Дженентек, Инк. Мультиспецифические антитела, аналоги антител, композиции и способы
WO2011075636A2 (en) 2009-12-18 2011-06-23 Amgen Inc. Wise binding agents and epitopes
EP2542582A4 (en) * 2010-03-02 2013-12-04 Abbvie Inc THERAPEUTIC PROTEINS LINKING TO DLL4
KR20130132824A (ko) 2010-11-08 2013-12-05 악셀레론 파마 인코포레이티드 Actriia 결합제 및 이의 용도
CA2857645A1 (en) 2011-11-30 2013-06-06 Wellstat Diagnostics, Llc Assays, antibodies, immunogens and compositions related to 5-fu
US20130177579A1 (en) * 2012-01-06 2013-07-11 Bioalliance C.V. Anti-transferrin receptor antibodies and methods using same
FR2987293B1 (fr) * 2012-02-27 2014-03-07 Michelin & Cie Procede et appareil pour realiser des objets tridimensionnels a proprietes ameliorees
US9549993B2 (en) * 2012-10-02 2017-01-24 Rutgers, The State University Of New Jersey Specific delivery of toxins conjugated with antibodies to activate matripase
US10195249B2 (en) 2012-11-02 2019-02-05 Celgene Corporation Activin-ActRII antagonists and uses for treating bone and other disorders
EP2917238A1 (en) 2012-11-08 2015-09-16 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof
US20140171356A1 (en) * 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
CA2922937A1 (en) * 2013-09-05 2015-03-12 Duke University Nav1.7 antibodies and methods of using the same
US10035847B2 (en) 2013-10-02 2018-07-31 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MA40008A (fr) 2014-06-13 2021-05-05 Acceleron Pharma Inc Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA41052A (fr) 2014-10-09 2017-08-15 Celgene Corp Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii
US11142571B2 (en) 2014-11-07 2021-10-12 Sesen Bio, Inc. IL-6 antibodies
TWI730949B (zh) 2014-12-03 2021-06-21 美商西建公司 活化素-ａｃｔｒｉｉ拮抗劑及治療貧血之用途
EP3419599A4 (en) 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
JP7145374B2 (ja) 2016-03-18 2022-10-03 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー インビボでの切断可能連結部分によって抗マトリプターゼ抗体にコンジュゲートされた化学療法剤を用いる腫瘍細胞の標的化
US20190224339A1 (en) * 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3565587A4 (en) * 2017-01-06 2020-12-16 The Regents of The University of California THERAPEUTIC ANTI-IGE ANTIBODIES AND RELATED METHODS AND COMPOSITIONS
CN118909118A (zh) 2017-09-07 2024-11-08 奥古斯塔大学研究所公司 程序性细胞死亡蛋白1抗体
CN114364694B (zh) * 2019-07-12 2024-05-10 国立大学法人京都大学 靶向usag-1分子的用于牙齿再生治疗的中和抗体
CN112180099B (zh) * 2020-09-15 2022-07-29 江南大学附属医院 子宫内膜异位症血清标志物的应用
JP2025504020A (ja) 2022-01-28 2025-02-06 ジョージアミューン・インコーポレイテッド Ｐｄ－１アゴニストであるプログラム細胞死タンパク質１に対する抗体
CN115322258B (zh) * 2022-05-31 2024-08-13 武汉真福医药股份有限公司 一种单克隆抗体qkma-1g41及其应用
CN115304677B (zh) * 2022-06-19 2024-08-16 湖北真福医药有限公司 一种抗枯草芽孢杆菌纤溶酶的单克隆抗体qkma-9a10及应用
CN116712533B (zh) * 2023-07-03 2024-02-02 广东暨安特博生物科技有限公司 一种sostdc1蛋白在制备治疗皮肤病产品中的应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2220912A1 (en) * 1995-06-05 1996-12-12 Gregg A. Hastings Human ccn-like growth factor
JP2004516013A (ja) * 2000-07-20 2004-06-03 ジェネンテック・インコーポレーテッド 血管形成に関連する障害を診断及び治療するための組成物と方法
US20040023356A1 (en) * 2002-06-14 2004-02-05 Robb Krumlauf Wise/Sost nucleic acid sequences and amino acid sequences
AU2005229009A1 (en) * 2004-03-23 2005-10-13 Amgen, Inc. Monoclonal antibodies specific for human OX40L (CD 134L)
FI3345607T3 (fi) * 2006-12-29 2022-11-30 Menetelmiä luun kasvun muuttamiseksi antamalla SOST- tai WISE-antagonistia tai antagonistia
KR101586617B1 (ko) * 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
AR076668A1 (es) * 2009-05-12 2011-06-29 Pfizer Anticuerpos especificos para dkk-1 y sus usos

Also Published As

Publication number Publication date
JP2011504501A (ja) 2011-02-10
WO2009070243A3 (en) 2009-10-29
BRPI0820387A2 (pt) 2015-05-26
CO6311002A2 (es) 2011-08-22
ZA201003578B (en) 2011-04-28
MX2010005656A (es) 2010-11-12
JP5583591B2 (ja) 2014-09-03
JP2014167002A (ja) 2014-09-11
US20090130114A1 (en) 2009-05-21
US20120003237A1 (en) 2012-01-05
US8043620B2 (en) 2011-10-25
IL205569A0 (en) 2010-12-30
MA31918B1 (fr) 2010-12-01
WO2009070243A2 (en) 2009-06-04
AU2008330125B2 (en) 2012-11-22
KR20100099193A (ko) 2010-09-10
EA201000844A1 (ru) 2011-10-31
CN101925611A (zh) 2010-12-22
US8309092B2 (en) 2012-11-13
AU2008330125A1 (en) 2009-06-04
CA2705879A1 (en) 2009-06-04
EP2220118A2 (en) 2010-08-25
TN2010000213A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
CO6311002A2 (es) Agentes fijadores y epitopos wise
UY33124A (es) Agentes y epítopos enlazados a wise
BRPI0821668A2 (pt) Uso
BRPI0818874A2 (pt) Liberação de agentes ativos
DE602006015876D1 (de) Schnellkupplung
BRPI0814252A2 (pt) Formulações de anticorpo
PT2889310T (pt) Formulações de anticorpo
EP1951275A4 (en) COMPOSITION AGAINST ADIPOSITAS
DE602006008118D1 (de) Entfernungsanordnung mit distaler freigabe
DK2719388T3 (da) Borholdige små molekyler som antiinflammatoriske midler
BRPI0807137A2 (pt) Agentes antiparasitários
GT200500269A (es) Procedimiento
BRPI0913945A2 (pt) agentes anti-inflamatórios
DK2178568T3 (da) Kontrastmidler
UY31563A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31562A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
UY31560A1 (es) Azolilmetiloxiranos, su uso y agentes que los contienen
DE602007007755D1 (de) Fußplatte
DE502005005266D1 (de) Dosierpumpe
DE602008000061D1 (de) Schnellkupplung
HN2006037713A (es) Compuestos utiles en terapia
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
PT1978981E (pt) Composições para uso vaginal
BRPI0812333A2 (pt) Composição de eliminação de odor para uso sobre superfícies macias
DK1868586T3 (da) Antiinflammatorisk formulering

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)